TABLE I.

Baseline Clinical Evaluation Characteristics of BeS and CBD Cases Stratified by Smoking Status

	Never smokers			Ever smokers
	BeS (n = 83)	CBD (n = 81)	P-value	BeS (n = 146)	CBD (n = 90)	P-value
Age at diagnosis (years)	50 (34.5–83)	50.3 (27–74)	1	53 (26–79)	54.8 (32–80)	0.37
Gender (M/F)	56 (67.5%)/27 (34.2%)	63 (77.8%)/18 (22.2%)	0.14	121 (82.9%)/25 (17.1%)	81 (90.0%)/9 (10.0%)	0.12
Race (%)			0.01			0.43
White	64 (84.2%)	77 (96.2%)		124 (93.2%)	85 (96.6%)
African American	8 (10.5%)	3 (3.8%)		4 (3.0%)	2 (2.3%)
Other	4 (5.3%)	0 (0.0%)		5 (3.8%)	1 (1.1%)
Industry (%)			0.002			<0.0001
Ceramics	1 (1.3%)	10 (12.5%)		3 (2.1%)	12 (13.3%)
Nuclear/aerospace	51 (63.7%)	32 (40.0%)		73 (51.0%)	23 (25.6%)
Recycling	8 (10.0%)	7 (8.7%)		12 (8.4%)	12 (13.3%)
Nuclear weapons	20 (25.0%)	55 (38.5%)		55 (38.5%)	43 (47.8%)
TreatmentaY/N	0 (0.0%)	10 (12.3%)	—b	0 (0.0%)	23 (25.5%)	—b
Years from first Be exposure to last exposure	18 (2–50)	20 (0–43)	0.68	21 (0–55)	22 (0–44)	0.37
Years from first Be exposure to diagnosis	11.5 (0–40)	13 (0–36)	0.45	14 (0–39)	16.5 (1–36)	0.23
Years from last exposure to diagnosis	1.7 (0–44)	1.7 (0–35)	0.69	3.7 (0–50)	1.5 (0–43)	0.32
Job			0.002			0.45
Machinist	4 (4.9%)	17 (21.0%)		25 (17.1%)	19 (21.1%)
Non-machinist	78 (95.1%)	64 (79.0%)		121 (82.9%)	71 (78.9%)
Job type			0.0004			0.01
Bystander	23 (28.7%)	7 (8.6%)		26 (17.8%)	7 (7.8%)
Dust disturber	17 (21.3%)	13 (16.1%)		40 (27.4%)	17 (18.9%)
Non-production	25 (31.3%)	25 (30.9%)		33 (22.6%)	19 (21.1%)
Production	15 (18.7%)	36 (44.4%)		47 (32.2%)	47 (52.2%)

Data presented are medians (ranges) or frequencies (percentages).

^aOral prednisone, methotrexate, pentoxifylline.

^bZero values; no statistical analysis.